CD22 and neoplasm: Further experiments on tumor (Raji, Mino, Jurkat) and normal immune cells (PBMC) showed that DOX–platelet–CD22 had a more pronounced cytotoxic effect on tumor cells and a reduced effect on PBMC [128].